Empagliflozin and Red Blood Cell 2,3-biphosphoglycerate Levels

Sponsor
Aristotle University Of Thessaloniki
Study ID
NCT06284850
Status
Unknown

Conditions

  • Cardiovascular Prevention
  • Empagliflozin
  • Hematocrit Change
  • SGLT2-Inhibitors
  • Tissue Oxygenation

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Empagliflozin10Mg Tab — DRUG
    TB JARDIANCE 10MG

Study Details

The aim of this study is to investigate the hypothesis that treatment with empagliflozin may have an impact on red blood cell 2,3-biphosphoglycerate levels affecting tissue oxygen supply and thus mediating part of the cardio- and reno- protective effect of SGLT-2 inhibitors.

Key Dates

Start date
Nov 30, 2023
Status verified
Feb 2024
Primary completion
Nov 30, 2025
Completion
Nov 30, 2025

Study Design

Enrollment
40 participants (estimated)

Arms

  • Arm: treatment with empagliflozin 10mg od
    empagliflozin 10mg OD

Primary Outcome Measure

Mean change in red blood cell 2,3-biphosphoglycerate levels (μmol/ml) [ Time Frame: 12 weeks ]

Central Contacts